362 related articles for article (PubMed ID: 26025324)
1. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Capello M; Lee M; Wang H; Babel I; Katz MH; Fleming JB; Maitra A; Wang H; Tian W; Taguchi A; Hanash SM
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025324
[TBL] [Abstract][Full Text] [Related]
2. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes.
Capello M; Fahrmann JF; Rios Perez MV; Vykoukal JV; Irajizad E; Tripathi SC; Roife D; Bantis LE; Kang Y; Kundnani DL; Xu H; Prakash LR; Long JP; Katayama H; Fleury A; Ferri-Borgogno S; Baluya DL; Dennison JB; Aguilar-Bonavides C; Casabar JP; Celiktas M; Do KA; Fiehn O; Maitra A; Wang H; Feng Z; Chiao PJ; Katz MH; Fleming JB; Hanash SM
JCO Precis Oncol; 2020 Nov; 4():426-436. PubMed ID: 35050739
[TBL] [Abstract][Full Text] [Related]
3. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
5. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
10. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Farshadi EA; Chang J; Sampadi B; Doukas M; Van 't Land F; van der Sijde F; Vietsch EE; Pothof J; Koerkamp BG; van Eijck CHJ
Clin Cancer Res; 2021 Dec; 27(23):6602-6612. PubMed ID: 34580113
[TBL] [Abstract][Full Text] [Related]
11. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
[TBL] [Abstract][Full Text] [Related]
13. Predicting a response to FOLFIRINOX in pancreatic cancer.
Nipp RD; Ryan DP
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025325
[No Abstract] [Full Text] [Related]
14. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
Janssen QP; van Dam JL; Prakash LR; Doppenberg D; Crane CH; van Eijck CHJ; Ellsworth SG; Jarnagin WR; O'Reilly EM; Paniccia A; Reyngold M; Besselink MG; Katz MHG; Tzeng CD; Zureikat AH; Groot Koerkamp B; Wei AC;
J Natl Compr Canc Netw; 2022 Jul; 20(7):783-791.e1. PubMed ID: 35830887
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Neyaz A; Tabb ES; Shih A; Zhao Q; Shroff S; Taylor MS; Rickelt S; Wo JY; Fernandez-Del Castillo C; Qadan M; Hong TS; Lillemoe KD; Ting DT; Ferrone CR; Deshpande V
Histopathology; 2020 Jul; 77(1):35-45. PubMed ID: 32031712
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.
Wang OH; Azizian N; Guo M; Capello M; Deng D; Zang F; Fry J; Katz MH; Fleming JB; Lee JE; Wolff RA; Hanash S; Wang H; Maitra A
PLoS One; 2016; 11(3):e0152300. PubMed ID: 27023625
[TBL] [Abstract][Full Text] [Related]
20. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Boone BA; Steve J; Krasinskas AM; Zureikat AH; Lembersky BC; Gibson MK; Stoller RG; Zeh HJ; Bahary N
J Surg Oncol; 2013 Sep; 108(4):236-41. PubMed ID: 23955427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]